ESHRE 2026: A turning point — IVF effectiveness is rising while cost and environment become the new bottlenecks

The big takeaway

This year's ESHRE cohort of studies signals two simultaneous transitions: routine IVF laboratory improvements have materially raised cumulative live-births while single embryo transfer has become the standard without compromising outcomes, and the dominant barriers to scaling fertility care are now affordability, uterine-level biology, and environmental influences rather than embryo viability alone.

Clinical performance: single-embryo strategies are no longer a trade-off

A multiclinic analysis of first IVF cycles covering 18,396 patients reported a roughly 68% cumulative live-birth rate across three cycles even though clinicians transferred a single embryo in over 95% of transfers and kept multiple-births under 3%, demonstrating that modern lab protocols—blastocyst culture, vitrification and freeze-all approaches—have pushed success rates upward while reducing obstetric risk.

That same dataset showed only a minority of patients received routine comprehensive genetic embryo screening, implying many clinics are achieving high outcomes without universal PGT-A; for investors this reframes where product value accrues—toward lab throughput, cryopreservation quality and process standardisation rather than blanket genetic testing.

Cryo-first era: frozen embryo transfers dominate

European monitoring data reported over 1.15 million ART cycles in 2023 and highlighted that frozen embryo transfers now account for the largest single share of activity—near 43%—with higher delivery rates per transfer than conventional fresh IVF and historically low multiple-delivery rates, validating investments in cryostorage capacity, remote embryo logistics, and FET-optimised endometrial preparation tools.

Cost is the demand lever — and it’s highly elastic

An international analysis spanning 22 countries that represent the vast majority of global ART activity found that halving out-of-pocket costs was associated with roughly a 2.7-fold rise in ART births; the study’s affordability metric ranged from modest fractions of median income to many multiples, showing that reducing the price barrier produces disproportionate increases in utilisation.

For investors that means business models which materially lower the per-baby economic burden—subscription financing, bundled multi-cycle packages, pay-for-outcome arrangements, and public-private reimbursement partnerships—are likely to unlock volume faster than incremental clinical tweaks alone.

Beyond the egg: uterine age and pregnancy loss reshape product need

Data from donor-egg cycles indicate that uterine ageing becomes clinically consequential around age 49: while donor oocytes preserve meaningful success, live-birth probabilities fall and miscarriage rates rise in older recipients, signalling an unmet need for diagnostics and interventions that characterise and improve endometrial receptivity rather than focusing solely on gamete quality.

At the same time, population-level English hospital data covering nearly a million miscarriage admissions and a quarter-million ectopic admissions over two decades show rising admissions in the post-pandemic period and persistent socioeconomic gradients—women from deprived communities face substantially higher rates—underscoring demand for scalable loss-care pathways, earlier outpatient triage, and investment in prevention and equity-focused service models.

Male factor and the environment: a growing scientific frontier

A large study of more than 2,000 men linked common air pollutants—ozone and nitrogen dioxide—to specific changes in sperm DNA methylation, including at an imprinted locus implicated in development, which introduces paternal environmental exposure as a plausible mechanism affecting fertility and potentially offspring health; this opens a new diagnostic category around sperm epigenetics and exposure-integrated risk profiling.

Complementary regional data from Spain showed large geographic disparities in semen parameters not explained by lifestyle, strengthening the case that environmental exposures (pollution, industrial chemicals) are modifiable population drivers and public-health levers for fertility outcomes.

Social license: public opinion is permissive but nuanced

A multi-country European survey of nearly 8,700 respondents found solid majorities supporting state-funded fertility care and more support than opposition for embryo research and certain genome-editing applications, suggesting a favourable social climate for investment in reproductive technologies—though regulators and publics remain selective, especially on new embryo research limits.

Where capital should flow next

• Lab automation and standardisation that raise blastocyst and vitrification consistency to drive single-embryo success at scale.
• Business models that cut per-patient out-of-pocket cost (multi-cycle bundles, outcome-based contracts, consumer financing) to unlock latent demand.
• Cryopreservation infrastructure, logistics and FET optimisation tools given FET’s growing share and superior delivery rates.
• Endometrial diagnostics and therapeutics targeting uterine receptivity, particularly for older recipients and donor-egg programs.
• Male-focused assays and epigenetic tests that integrate environmental exposure data to broaden fertility diagnostics.
• Digital care pathways for pregnancy loss and ectopic management that reduce hospital admissions and address socioeconomic gaps.
• Environmental health data platforms that connect pollution exposure with reproductive outcomes for population-level interventions and payer use cases.
• Policy and reimbursement playbooks that aim to secure multi-cycle coverage rather than one-off funding to maximise birth outcomes.

Risks and timelines: many of these opportunities sit at the intersection of clinical validation, regulatory scrutiny and payor negotiation; diagnostics and lab hardware can scale faster, while therapeutics and population-level policy changes will take longer and require stronger evidence and advocacy.

Bottom line: the clinical ceiling on single-embryo IVF has risen, shifting value to cost reduction, throughput and non-oocyte biology. Investors should prioritise companies that demonstrably reduce the cost-per-live-birth, expand FET capacity and deliver actionable uterine or paternal diagnostics that meaningfully change care decisions.

“The market is moving from 'more embryos' to 'smarter systems' — lower cost-per-baby, cryo-scale and uterine diagnostics will determine winners.”

Fern Capital Research